RA Capital Nexus Fund II, L.P., Director at Cytek Biosciences, Inc. (CTKB), bought 840,760 shares at $12.99 ($11.1M) on 2022-02-25, disclosed to the SEC on 2022-02-25.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.41 | 214,922 | $2.9M | 25.9% |
| 2 | $13.41 | 214,922 | $2.9M | 25.9% |
| 3 | $13.03 | 186,467 | $2.4M | 21.9% |
| 4 | $13.03 | 186,467 | $2.4M | 21.9% |
| 5 | $12.99 | 18,991 | $247K | 2.2% |
| 6 | $12.99 | 18,991 |
| $247K |
| 2.2% |
| Total | $13.22 avg | 840,760 | $11.1M | 100% |
| Filing → |
| ANTX | BUY | 2023-08-22 | $16.0M | — | Filing → |
| JANX | BUY | 2023-07-21 | $12.3M | — | Filing → |
| DICE | BUY | 2023-03-30 | $29.6M | — | Filing → |